Entropy Neurodynamics (ASX: ENP, formerly Tryp Therapeutics) is a clinical-stage biotech developing psilocin therapies w/ psychotherapy for unmet medical needs.
Joined July 2020
- Tweets 685
- Following 186
- Followers 1,395
- Likes 486
278 Photos and videos
$ENP advises the independent DSMB recommended progression of TRP-8803 Phase 2 BED trial to Cohort 2 w/ no protocol changes, confirming favourable safety & tolerability profile in Cohort 1 & supporting continued program development. Read more: cdn-api.markitdigital.com/ap… #ASX #Biotech
11
$ENP advises the independent DSMB recommended progression of TRP-8803 Phase 2 BED trial to Cohort 2 w/ no protocol changes, confirming favourable safety & tolerability profile in Cohort 1 & supporting continued program development. Read more: cdn-api.markitdigital.com/ap… #ASX #Biotech
51
TRP-8802 validated the opportunity in treatment-resistant #IBS. The next question is whether $ENP
’s proprietary IV-infused #psilocin therapy can unlock even greater consistency, control and scalability. Dr Erin Mauney explains. youtu.be/KAnfXq8mdmE #biotech
1
2
49
TRP-8802 helped validate #IBS indication & gut-brain mechanism. @InvestorStream_ asked Dr Erin Mauney how $ENP ’s proprietary IV-infused psilocin therapy, TRP-8803, could build on findings & potentially deliver even more consistent treatment experience. youtu.be/KAnfXq8mdmE
2
58
As #psychedelic therapies continue to evolve, understanding how and why they work is becoming just as important as clinical outcomes. Dr Erin Mauney explains what latest #IBS data reveals about the gut-brain axis and future treatment opportunities. youtu.be/KAnfXq8mdmE $ENP
1
33
One of the most important findings from $ENP’s Phase 2a #IBS study wasn't just the response rate. It was the evidence supporting a potential underlying mechanism of action through the gut-brain axis. youtu.be/KAnfXq8mdmE #biotech #ASX
1
24
Q: Could the key to treating #IBS lie beyond the gut itself? Dr Erin Mauney discusses how the study's mechanistic findings are helping researchers better understand the role of the gut-brain axis in IBS. youtu.be/KAnfXq8mdmE $ENP #biotech
1
1
43
Q: The Phase 2a IBS study delivered more than strong efficacy data. Researchers also observed a link between symptom improvement & changes in key psychological measures, providing further support for the gut-brain axis hypothesis. youtu.be/KAnfXq8mdmE $ENP
1
1
57
Following the presentation of $ENP's Phase 2a #IBS results, Principal Investigator Dr Erin Mauney discusses the clinical outcomes, the gut-brain connection and why the study's findings could represent an important step forward in treatment-resistant IBS. youtu.be/KAnfXq8mdmE
1
1
51
Q: What happens when therapy delivers meaningful improvements in patients who've failed multiple treatment options? Dr Erin Mauney breaks down the clinical insights behind $ENP's TRP-8802 IBS data & what it could mean for millions living w/ #IBS. youtu.be/KAnfXq8mdmE
1
2
85
TRP-8802 validated the opportunity in treatment-resistant #IBS. The next question is whether $ENP
’s proprietary IV-infused #psilocin therapy can unlock even greater consistency, control and scalability. Dr Erin Mauney explains. youtu.be/KAnfXq8mdmE #biotech
1
38
TRP-8802 helped validate #IBS indication & gut-brain mechanism. @InvestorStream_ asked Dr Erin Mauney how $ENP ’s proprietary IV-infused psilocin therapy, TRP-8803, could build on findings & potentially deliver even more consistent treatment experience. youtu.be/KAnfXq8mdmE
1
1
112
Q: $ENP Phase 2a IBS study showed 75% response rate in treatment-resistant patients, one of strongest efficacy signals in indication. @InvestorStream_ spoke w/ Principal Investigator Dr Erin Mauney on what’s driving results & significance for IBS treatment youtu.be/KAnfXq8mdmE
1
2
66
As #psychedelic therapies continue to evolve, understanding how and why they work is becoming just as important as clinical outcomes. Dr Erin Mauney explains what latest #IBS data reveals about the gut-brain axis and future treatment opportunities. youtu.be/KAnfXq8mdmE $ENP
1
2
89
One of the most important findings from $ENP’s Phase 2a #IBS study wasn't just the response rate. It was the evidence supporting a potential underlying mechanism of action through the gut-brain axis. youtu.be/KAnfXq8mdmE #biotech #ASX
1
22
Q: Could the key to treating #IBS lie beyond the gut itself? Dr Erin Mauney discusses how the study's mechanistic findings are helping researchers better understand the role of the gut-brain axis in IBS. youtu.be/KAnfXq8mdmE $ENP #biotech
1
46
Q: The Phase 2a IBS study delivered more than strong efficacy data. Researchers also observed a link between symptom improvement & changes in key psychological measures, providing further support for the gut-brain axis hypothesis. youtu.be/KAnfXq8mdmE $ENP
1
27
Following the presentation of $ENP's Phase 2a #IBS results, Principal Investigator Dr Erin Mauney discusses the clinical outcomes, the gut-brain connection and why the study's findings could represent an important step forward in treatment-resistant IBS. youtu.be/KAnfXq8mdmE
1
1
31
Q: What happens when therapy delivers meaningful improvements in patients who've failed multiple treatment options? Dr Erin Mauney breaks down the clinical insights behind $ENP's TRP-8802 IBS data & what it could mean for millions living w/ #IBS. youtu.be/KAnfXq8mdmE
2
42
Q: $ENP Phase 2a IBS study showed 75% response rate in treatment-resistant patients, one of strongest efficacy signals in indication. @InvestorStream_ spoke w/ Principal Investigator Dr Erin Mauney on what’s driving results & significance for IBS treatment youtu.be/KAnfXq8mdmE
1
2
2
179